ibrutinib

CD19 molecule ; Homo sapiens







12 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33661190 Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). 2021 Apr 1 1
2 33932067 Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. 2021 Jul 3
3 31899702 Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. 2020 May 2
4 32563910 Ibrutinib is not an effective drug in primografts of TCF3-PBX1. 2020 Oct 1
5 32581054 CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. 2020 Jun 2
6 32861289 Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. 2020 Oct 1
7 32876369 Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro. 2020 Nov 3
8 29743179 A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. 2018 Aug 2 4
9 27677739 Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. 2017 Jan 1
10 28715249 Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. 2017 Sep 10 2
11 26813675 Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. 2016 Mar 3 1
12 23940282 Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. 2013 Oct 3 1